Sunday 11 October 2026 Export all AMGN data to Excel Powerpack

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

414.87 7.43 +1.82%
Market cap
$220.3B
P/E
25.6×
Fwd P/E
22.7×
Dividend yield
2.40%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100

Amgen Inc. 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 6:29 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 1, 2026: 13 added · 6 removed · 63 modified; 6 with only figures updated; 5 moved without change

  1. Modified

    The following MD&A is intended to assist the reader in understanding Amgen’s business. MD&A is provided as a supplement to, and should be read in conjunction with, both the consolidated financial statements and accompanying notes of our Annual Report on Form 10-K for the year ended December 31, 2025, and the condensed consolidated financial statements and accompanying notes of this Quarterly Report on Form 10-Q and our AnnualQuarterly Report on Form 10-K10-Q for the yearquarter ended DecemberMarch 31, 20252026. Our results of operations discussed in MD&A are presented in conformity with GAAP. Amgen operates in one operating segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.

81 more changes in this Item, word by word, in Powerpack.

Powerpack